Optimizing microfluidic LNP formulations with in-line particle size and concentration measurements
November 17th 2022Thursday, November 17, 2022 Session 1: 8 am PST | 11 am EST | 5 pm CET Session 2: 10 am CET | 9 am GMT | 6 pm JST Session 3: 10am JST | 5 pm PST Learn how to automate LNP production with in-line particle size and concentration measurements using multi-angle light scattering (MALS) and dynamic light scattering (DLS).
Oligonucleotide Therapeutics: Chemistry and therapeutic modalities
November 3rd 2022Thursday, November 3, 2022 Session 1: 10 am CST | 11 am JST (APAC) Session 2: 1 pm GMT | 2 pm CET (EMEA) Session 3: 2 pm EST | 11 am PDT (Americas) (Americas)Register for our educational webinar series presented by Professor Tom Brown, University of Oxford and learn more about the advances in oligonucleotide therapeutics and diagnostics!
Intact Mass Analysis of Multispecific Antibodies: Automation and Data Management
October 25th 2022Tuesday, October 25th, 2022 at 11am EDT|8am PDT|4pm BST|5pm CEST Discover approaches for medium- and high-throughput analysis of multispecific antibodies using Byos software with AWS automation workflows. In this presentation, we will discuss how to use this data to select optimal therapeutic candidates produced on our high-throughput protein production platform.
New Developments in Mass Spectrometry-Based Single-Cell Proteomics
October 21st 2022Fri, Oct 21, 2022 11:00 AM EDT Learn how Karl Mechtler has developed an end-to-end workflow to efficiently prepare and analyze samples for single-cell proteomics by mass spectrometry. This workflow enables direct injection of single cells to identify approximately 1,500 protein groups per analytical run and uncover the surprising heterogeneity of cell populations.
Novel Oligonucleotide Sample Clean-up and Method Optimizations
October 19th 2022Wednesday, October 19th 2022, 11am EDT | 8am PDT | 4pm BST | 5pm CEST In this webinar, we will give an overview of sample preparation and LC-MS strategies for synthetic oligonucleotides, including how to adjust experimental design depending on the oligo and sample matrix. Additionally, novel small volume clean-up solutions for oligonucleotides will be explored to further optimize challenging methods.
Translate your idea into product: AI-driven antibody discovery at Evotec
October 18th 2022October 18, 2022, 2pm EDT Evotec recently hosted its Innovation Week webinar series - 5 virtual sessions over 5 days. Session 5 discusses Evotec’s capabilities for supporting all activities across the R&D continuum for biotherapeutics, i.e. Discovery and optimization of novel antibodies for specific disease targets, evaluation of lead antibodies for disease efficacy and safety, alongside process development and manufacturing
How to Find Success with Lentiviral Production Using Fixed Bed Bioreactor Technology
October 17th 2022Monday, October 17, 2022 at 11am EDT | 4pm BST | 5pm CEST Why would a CDMO to leverage fixed-bed bioreactor technology to develop and produce GMP lentiviral vectors? Join us for a discussion on increasing quality and decreasing time and cost to accelerate time to clinic and market for lentiviral products with technology.
Best Practices in HCP Assay Development and Integration of Advanced Orthogonal Methods
October 11th 2022Tuesday, October 11, 2022 at 11 AM EDT Learn about best practices in Host Cell Protein (HCP) assay development and qualification. Improve your understanding of the advanced orthogonal methods used to fully characterize HCPs in your process
Characterization of Biotherapeutic Beasts by Mass Spectrometry
September 29th 2022Thursday, September 29, 2022 at 7am PT | 10am ET | 4pm CET Novel methods have been developed and applied on Biotherapeutics Beasts in the half Megadalton to 3-4 MDa range to measure AAV Full:Empty genome ratio using charge detection mass spectrometry on the Q Exactive UHMR mass spectrometer with Direct Mass Technology mode.
Preparing biologics for commercialization: strategies to reduce risk and optimize outcomes
September 28th 2022Wednesday, September 28, 2022 at 10 AM EST | 4 PM CET Optimize your late-phase strategy to prepare your biologic for commercialization. CDMO experts share their time-tested best practices on how to adapt for uncertain market demand to get your drug to market on time.